EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis and anticancer potential of new peptide conjugates via urokinase inhibition: biological and in silico studies

Taghreed Abdelstar Sheha, Amany S Mostafa, Shahenda M El-Messery, Hassan M Eisa

Bioorganic Chemistry · 2026-11 · 183 · 110602

DOI: 10.1016/j.bioorg.2026.110602 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-11. Verfasst von Taghreed Abdelstar Sheha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, 35516 Mansoura, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Urokinase-Type Plasminogen Activator, Drug Design, Peptides. Die Arbeit nennt 104 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A new series of peptide derivatives was designed, synthesized, and structurally confirmed. The target compounds were evaluated for their anticancer activity against four human cancer cell lines: HepG-2 (hepatocellular carcinoma), MCF-7 (breast carcinoma), HeLa (cervical epithelioid carcinoma), and MDA-MB-231 (triple-negative breast cancer). Eight compounds exhibited exceptional broad-spectrum cytotoxicity, outperforming the standard drug Doxorubicin across most tested cell lines. Consequently, their inhibitory activity against the urokinase-type plasminogen activator (uPA) enzyme was evaluated using Rivaroxaban as a reference standard. Hybrids bearing heterocyclic acid moieties, compounds 13 and 18, emerged as the most potent uPA inhibitors, displaying IC50 of 0.546 ± 0.018 μM and 0.698 ± 0.023 μM, respectively-both superior to Rivaroxaban (IC50 = 0.729 ± 0.024 μM). Mechanistic studies on MCF-7 cells demonstrated that compounds 13 and 18 induced cell cycle arrest at the G2/M phase and triggered apoptosis (31.41% and 23.25%, respectively) with low necrosis (3.81% and 2.94%, respectively, vs. 1.71% in control). RT-qPCR analysis revealed significant upregulation of pro-apoptotic Bax (6.55 and 4.07-fold) and downregulation of anti-apoptotic Bcl-2 (0.45- and 0.22-fold), confirming activation of apoptosis pathways. Molecular docking, binding energy calculations, and surface mapping against uPA highlighted critical interactions with key active site residues (Gly219, Cys220, Arg217, and Gln192), rationalizing their potent enzymatic inhibition. Furthermore, molecular dynamics simulations provided critical atomistic insights into the conformational stability and binding mechanisms, highlighting the therapeutic potential of the identified compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsUrokinase-Type Plasminogen ActivatorDrug DesignPeptidesHumansDrug Screening Assays, AntitumorCell ProliferationApoptosisStructure-Activity RelationshipMolecular Docking SimulationMolecular StructureDose-Response Relationship, DrugCell Line, TumorBlood Proteins

Stichwörter der Autor:innen

AnticancerHeterocyclesPeptidesUrokinase

Substanzen

Antineoplastic AgentsUrokinase-Type Plasminogen ActivatorPeptidesurokinase inhibitorBlood Proteins

Autor:innen und Institutionen

  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, 35516 Mansoura, Egypt.
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, 35516 Mansoura, Egypt; Pharmacy Center of Scientific Excellence, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, 35516 Mansoura, Egypt. Electronic address: habib2001@mans.edu.eg.

Zitieren

APA

Sheha, T. A., Mostafa, A. S., El-Messery, S. M., & Eisa, H. M. (2026). Design, synthesis and anticancer potential of new peptide conjugates via urokinase inhibition: biological and in silico studies. Bioorganic Chemistry, 183, 110602. https://doi.org/10.1016/j.bioorg.2026.110602

Vancouver

Sheha TA, Mostafa AS, El-Messery SM, Eisa HM. Design, synthesis and anticancer potential of new peptide conjugates via urokinase inhibition: biological and in silico studies. Bioorganic Chemistry. 2026;183:110602. doi:10.1016/j.bioorg.2026.110602

BibTeX
@article{Sheha2026,
  author = {Sheha, Taghreed Abdelstar and Mostafa, Amany S and El-Messery, Shahenda M and Eisa, Hassan M},
  title = {Design, synthesis and anticancer potential of new peptide conjugates via urokinase inhibition: biological and in silico studies},
  journal = {Bioorganic Chemistry},
  year = {2026},
  volume = {183},
  pages = {110602},
  doi = {10.1016/j.bioorg.2026.110602}
}
Kostenlos starten →